Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Fortress Biotech Inc FBIO

Alternate Symbol(s):  FBIOP

Healthcare Biotechnology
Fortress Biotech, Inc. is a biopharmaceutical company that acquires, develops and commercializes pharmaceutical and biotechnology products and product candidates. The Company markets its various branded dermatology products, Qbrexza, Accutane, Amzeeq, Zilxi, Ximino, Exelderm and Targadox. Qbrexza (glycopyrronium 2.4%) is a medicated cloth towelette for the treatment of primary axillary... see more

Recent & Breaking News (NDAQ:FBIO)

Checkpoint Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire November 19, 2019

Fortress Biotech Ranked in Top 10 of Deloitte's 2019 Technology Fast 500(TM)

GlobeNewswire November 14, 2019

Fortress Biotech Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

GlobeNewswire November 12, 2019

Mustang Bio Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

GlobeNewswire November 12, 2019

Checkpoint Therapeutics Announces Presentation of Anti-PD-L1 Cosibelimab Data at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

GlobeNewswire November 8, 2019

Checkpoint Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

GlobeNewswire November 7, 2019

Mustang Bio Announces MB-107 Lentiviral Gene Therapy and MB-106 CD20-Targeted CAR T Data Selected for Presentations at 61st American Society of Hematology Annual Meeting

GlobeNewswire November 6, 2019

Avenue Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

GlobeNewswire November 4, 2019

Avenue Therapeutics Announces Publication of IV Tramadol Phase 1 Clinical Data in Clinical Pharmacology in Drug Development

GlobeNewswire October 28, 2019

Fortress Biotech to Participate in the 5th Annual Dawson James Small Cap Growth Conference

GlobeNewswire October 24, 2019

Mustang Bio Announces Dosing of First Participant in Phase 1 Clinical Trial of MB-108 (Oncolytic Virus C134) to Treat Glioblastoma

GlobeNewswire October 24, 2019

Avenue Therapeutics to Present Phase 3 Bunionectomy Study of IV Tramadol at the American Society of Anesthesiologists Annual Meeting

GlobeNewswire October 18, 2019

Mustang Bio Announces City of Hope Receives $4.1 Million in Grant Awards for Recently Opened First-of-Its-Kind Clinical Trial for Patients with Recurrent Malignant Glioma

GlobeNewswire October 10, 2019

Checkpoint Therapeutics Announces Presentation of Positive Interim Clinical Results for Anti-PD-L1 Cosibelimab at the European Society for Medical Oncology (ESMO) Congress 2019

GlobeNewswire September 30, 2019

Checkpoint Therapeutics to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

GlobeNewswire September 26, 2019

Mustang Bio to Participate in October 2019 Investor Conferences

GlobeNewswire September 26, 2019

Fortress Biotech to Present at October 2019 Investor Conferences

GlobeNewswire September 26, 2019

Mustang Bio Announces Phase 1 Clinical Trial Evaluating MB-105 for Prostate Stem Cell Antigen-Positive Castration-Resistant Prostate Cancer Enrolling Patients at City of Hope

GlobeNewswire September 23, 2019

Checkpoint Therapeutics Announces Data Presentation at the European Society for Medical Oncology (ESMO) Congress 2019

GlobeNewswire September 16, 2019

Mustang Bio to Present at Scientific Conferences in September 2019

GlobeNewswire September 9, 2019